6Y4.F VICORE PHARMA HOLDING AB
- Market cap
- EUR 281M
- P/E
- -
- P/B
- 3.57x
- ROE
- -58.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6Y4.F undervalued?
Graham numberThe Graham number of VICORE PHARMA HOLDING AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
VICORE PHARMA HOLDING AB fundamental analysis
No fundamental analysis for VICORE PHARMA HOLDING AB yet.
VICORE PHARMA HOLDING AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About VICORE PHARMA HOLDING AB
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational…
Full company profileVICORE PHARMA HOLDING AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
VICORE PHARMA HOLDING AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 109M | 3.82M | 5.63M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 109M | 3.82M | 5.63M |
| Operating Income | -293M | -287M | -321M | -190M | -454M | -548M |
| EBITDA | - | -285M | -308M | -167M | -477M | -501M |
| Net Income | -296M | -288M | -311M | -169M | -477M | -503M |
| EPS | -4.02 | -3.43 | -2.71 | -0.72 | -1.70 | -1.79 |
| Balance Sheet | ||||||
| Total Assets | 451M | 338M | 498M | 1.20B | 1.22B | 930M |
| Total Liabilities | 67.9M | 48.9M | 42.4M | 66.2M | 123M | 76.2M |
| Shareholders' Equity | 383M | 289M | 455M | 1.13B | 1.10B | 854M |
| Cash & Short-term Investments | 294M | 257M | 334M | 1.16B | 578M | 429M |
| Cash Flow | ||||||
| Operating Cash Flow | -265M | -300M | -250M | -165M | -376M | -547M |
| Capital Expenditure | 0.00 | 3.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -265M | -303M | -250M | -165M | -376M | -547M |
| Ratios | ||||||
| ROE | -77.3% | -99.8% | -68.3% | -14.9% | -43.6% | -58.9% |
| ROA | -65.7% | -85.3% | -62.5% | -14.1% | -39.2% | -54.1% |
| Net Profit Margin | - | - | - | -154.2% | -12,509.1% | -8,932.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
VICORE PHARMA HOLDING AB dividends
VICORE PHARMA HOLDING AB has not paid dividends in the last 5 fiscal years.
Who owns VICORE PHARMA HOLDING AB
- Insiders 13.27%
- Institutions 59.25%
- Public & others 27.49%
- Shares outstanding 282M
- Free float 201M
VICORE PHARMA HOLDING AB company profile
- Company name
- VICORE PHARMA HOLDING AB
- Ticker
- 6Y4.F
- ISIN
- SE0007577895
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 46
- Fiscal year end
- December
- Address
- Kornhamnstorg 53, Stockholm, Sweden, 111 27
- Phone
- 46 3 17 88 05 60
- Website
- vicorepharma.com
About VICORE PHARMA HOLDING AB
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. It has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.
VICORE PHARMA HOLDING AB management
10- Mr. Ahmed S. Mousa J.D.Chief Executive Officer · born 1984
- Mr. Hans Jeppsson Ph.D.Chief Financial Officer
- Mr. Mikael NygårdChief Operating Officer
- Ms. Helen BarkerChief Technology Officer
- Dr. Rob Slack Ph.D.Chief Scientific Officer
- Ms. Nina CarlenChief Administrative Officer
- Mr. Karam HijjiGeneral Counsel
- Mr. Jason HoffmanVP & Head of Human Resources
- Ms. Johanna Grans Ph.D.Head of Non-Clinical Development
- Mr. Jimmie HofmanChief Business Officer